University of B.C. researchers have developed a groundbreaking coating that could make medical devices safer for millions of patients, reducing the risks associated with blood clots and dangerous bleeding.
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design | Psychedelic Invest
Cybin Inc. announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder
March 14, 2024